成人院外心脏骤停中肾上腺素给药:骨内与静脉通路的比较
该回顾性研究纳入112例接受现场复苏的成人院外心脏骤停患者,比较由急救员建立的骨内通路(22例)与静脉通路(90例)在通路建立成功率、肾上腺素给药率和给药时间上的差异。骨内通路的通路建立成功率中位数(100% vs 33%,P<0.001)和肾上腺素给药率(100% vs 52%,P<0.001)均显著高于静脉通路;骨内通路与静脉通路相比,调整后的比值比为32.445(95%CI 1.844-570.861)。Kaplan-Meier累积时间事件分析显示,骨内通路的给药时间显著更短(P<0.001)。
要点
- 骨内通路建立成功率中位数为100%,静脉通路为33%(P<0.001)。
- 骨内通路肾上腺素给药率为100%,静脉通路为52%(P<0.001)。
- 骨内通路与静脉通路相比,调整后的比值比为32.445(95%CI 1.844-570.861)。
- Kaplan-Meier累积时间事件分析显示,骨内通路的肾上腺素给药时间显著更短(P<0.001)。
适用人群与场景
- 纳入标准:接受现场复苏尝试、由急救员建立静脉或骨内通路的成人院外心脏骤停患者。
- 排除标准:数据缺失、建立血管通路前恢复自主循环、转运途中发生心脏骤停、未进行复苏、调度员未识别的院外心脏骤停。
- 场景:院前急救,由急救员(桃园消防局三民站)实施。
研究设计与关键结果
- 研究类型:回顾性研究,由桃园消防局三民站实施;静脉通路数据收集于2020年1月1日至2020年12月31日,骨内通路数据收集于2021年1月1日至2021年3月10日。
- 共纳入112例成人患者(男71例,女41例,平均年龄67岁);静脉通路组90例,骨内通路组22例。
- 通路建立成功率中位数:骨内通路100% vs 静脉通路33%(P<0.001)。
- 肾上腺素给药率:骨内通路100% vs 静脉通路52%(P<0.001)。
- 骨内通路与静脉通路相比,调整后的比值比为32.445(95%CI 1.844-570.861)。
- Kaplan-Meier累积时间事件分析显示,骨内通路的肾上腺素给药时间显著更短(P<0.001)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在成人院外心脏骤停的院前复苏中,由急救员建立骨内通路与更高的通路建立成功率和肾上腺素给药率、更短的给药时间相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The benefits and risks of the intraosseous (IO) route for vascular access in patients with out-of-hospital cardiac arrest (OHCA) remain controversial. This study compares the success rates of establishing the access route, epinephrine administration rates, and time-to-epinephrine between adult patients with OHCA with IO access and those with intravenous (IV) access established by paramedics in the prehospital setting.
METHODS: This was a retrospective study conducted by the San-Min station of Taoyuan Fire Department. Data for IV access were collected between January 1, 2020, and December 31, 2020. Data for IO access were collected between January 1, 2021, and March 10, 2021. Inclusion criteria were adult patients with OHCA who received on-scene resuscitation attempts and in whom either IV or IO route access was established by paramedics. Exclusion criteria were missing data, return of spontaneous circulation before establishing vascular access, cardiac arrest en route to hospital, patients not resuscitated, and OHCA unidentified by the dispatcher. Exposure was defined as IV route vs. IO route (EZ-IO®). The outcome measurements were per-patient based success rates of route establishment (successes/attempts), administration rates of epinephrine (epinephrine administered per case/enrolled OHCAs), and odds ratios of IV versus IO on epinephrine administration. We used nonparametric Mann-Whitney rank sum tests for the analysis in continuous variables and Fisher's exact tests for the analysis of categorical variables and the outcomes. Firth logistic regression method was used for sparse data. Factors associated with epinephrine administration other than vascular access were also analyzed. Time-to-epinephrine (defined as time from paramedic arrival to epinephrine injection) was reviewed and calculated by two independent observers and the Kaplan-Meier method was used to compare the two access routes.
RESULTS: A total of 112 adult patients were enrolled in the analysis, including 71 men and 41 women, with an average age of 67 years. There were 90 IV access cases and 22 IO access cases. The groups were compared for median success rates of route establishment (33% vs. 100%, P < 0.001) and administration rates of epinephrine (52% vs. 100%, P < 0.001). The adjusted odds ratio of IO versus IV was 32.445, 95% confidence interval (CI) of 1.844-570.861. Time-to-epinephrine was significantly shorter in the cumulative time-event analysis by the Kaplan-Meier method (P < 0.001).
CONCLUSION: The IO route was significantly associated with higher success rates of route establishment, epinephrine administration, and shorter time-to-epinephrine in the prehospital resuscitation of adult patients with OHCA.
参考来源
- Yang SC, Hsu YH, Chang YH, et al. Epinephrine administration in adults with out-of-hospital cardiac arrest: A comparison between intraosseous and intravenous route. Am J Emerg Med. 2023. PMID: 36806977. doi:10.1016/j.ajem.2023.02.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。